Literature DB >> 8837948

Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry.

J Cai1, J Henion.   

Abstract

The in vitro metabolism of D-lysergic acid diethylamide (LSD) by human liver microsomes was investigated. Tandem mass spectrometric techniques, using precursor and neutral loss scans, were employed in the initial search for drug metabolites. The determination of LSD human liver in vitro metabolites was performed by high-performance liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry. Two new in vitro metabolites, lysergic acid ethylamide (LAE) and 2-oxo-LSD, were positively identified; their structures were established by comparing with reference standards. Several other possible in vitro metabolites detected were suggested to be mono- and trioxylated metabolites of LSD. The major metabolic route of LSD by human liver microsomes is deethylation. Some results with LSD-positive human urine are presented. Among the LSD-related compounds detected in human urine specimens, iso-LSD was present at the highest concentration, followed by nor-LSD and isonor-LSD. Low concentrations of LAE and iso-LAE were also found in these urine specimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837948     DOI: 10.1093/jat/20.1.27

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  9 in total

1.  Multidimensional chromatography coupled with mass spectrometry for target-based screening.

Authors:  Y F Hsieh; N Gordon; F Regnier; N Afeyan; S A Martin; G J Vella
Journal:  Mol Divers       Date:  1997       Impact factor: 2.943

Review 2.  Capillary electrophoresis in pharmaceutical analysis.

Authors:  L A Holland; N P Chetwyn; M D Perkins; S M Lunte
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

3.  Screening for drugs in serum by electrospray ionization/collision-induced dissociation and library searching.

Authors:  W Weinmann; A Wiedemann; B Eppinger; M Renz; M Svoboda
Journal:  J Am Soc Mass Spectrom       Date:  1999-10       Impact factor: 3.109

4.  Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.

Authors:  Patrick C Dolder; Matthias E Liechti; Katharina M Rentsch
Journal:  J Clin Lab Anal       Date:  2017-05-26       Impact factor: 2.352

Review 5.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

6.  Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Simon P Elliott; Jason Wallach; Tristan Colestock; Timothy E Burrow; Stephen J Chapman; Alexander Stratford; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-06-06       Impact factor: 3.345

7.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

8.  LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor.

Authors:  Donata Favretto; Giampietro Frison; Sergio Maietti; Santo Davide Ferrara
Journal:  Int J Legal Med       Date:  2006-02-23       Impact factor: 2.791

9.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.